

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

LNCaP C4-2B

RRID:CVCL_4784

Type: Cell Line

Proper Citation

RRID:CVCL_4784

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4784

Proper Citation: RRID:CVCL_4784

Description: Cell line LNCaP C4-2B is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:8168083](#), [PMID:15162376](#), [PMID:24587179](#), [PMID:33298586](#), [PMID:35502546](#)

Comments: Characteristics: Bone metastatic., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP C4-2B

Synonyms: C4-2B, C4-2 B, C4-2 Bone metastatic

Cross References: BTO:BTO_0004959, EFO:EFO_0006365, ATCC:CRL-3315, cancercellines:CVCL_4784, ChEMBL-Cells:ChEMBL4295450, ChEMBL-Targets:ChEMBL4296461, Cosmic:1689709, ENCODE:ENCBS002MOV, ENCODE:ENCBS108UKE, ENCODE:ENCBS109FVF, ENCODE:ENCBS159HRH, ENCODE:ENCBS328CYG, ENCODE:ENCBS391IVJ, ENCODE:ENCBS440KYC, ENCODE:ENCBS582KTC, ENCODE:ENCBS728XMM, ENCODE:ENCBS947VNK, GEO:GSM648816, GEO:GSM3145591, GEO:GSM3145695, Progenetix:CVCL_4784, PubChem_Cell_line:CVCL_4784, Wikidata:Q54902815

ID: CVCL_4784

Hierarchy: cvcl_4782

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260829T234525+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP C4-2B.

No alerts have been found for LNCaP C4-2B.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 274 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yang M, et al. (2026) MCCC2 stabilizes LTBP1 via suppressing SMURF1-dependent ubiquitination to drive bone metastasis in prostate cancer. *Oncogene*, 45(28), 2779.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Portman N, et al. (2026) Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. *EBioMedicine*, 123, 106058.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Gulla S, et al. (2026) MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. *Cancer research*, 86(9), 2143.

Wilson A, et al. (2026) Inhibiting stearyl-CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response. *FEBS letters*, 600(7), 1043.

Bidkar AP, et al. (2026) Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1540.

Semenova G, et al. (2025) Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. *bioRxiv : the preprint server for biology*.

Zhang Y, et al. (2025) Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(29), e04192.

Zhang L, et al. (2025) Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(10), 2034.

Li S, et al. (2025) Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer. *bioRxiv : the preprint server for biology*.

Bizzaro CL, et al. (2025) Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles. *Molecular cancer research : MCR*, 23(6), 542.

Nepali PR, et al. (2025) Effect of TGF- β mediated phenotypic changes on prostate cancer cell anoikis response. *Oncogene*, 44(50), 4835.

Sun F, et al. (2025) CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. *Cell death & disease*, 17(1), 113.

Leach DA, et al. (2025) Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis. *Molecular oncology*.

Johnson CS, et al. (2025) Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 739.

Ganapathy K, et al. (2025) Reciprocal regulation between DNMT3A/3B and microRNAs miRs-299-3p/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer. *Heliyon*, 11(3), e41948.

Kudo KI, et al. (2025) Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells. *bioRxiv : the preprint server for biology*.

Bach CA, et al. (2025) A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. *PloS one*, 20(9), e0329014.

Wang Y, et al. (2025) Trillin inhibits MAP3K11/NF- κ B/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer. *iScience*, 28(2), 111505.